| SWITZERLAND |  |
Since 2009, Cytosurge AG develops, manufactures, and distributes state-of-the-art nanotechnology solutions and systems based on its patented FluidFM® technology. At the heart of the technology are the hollow FluidFM probes, which have apertures down to 300 nm, enabling the handling of femtoliter volumes. With its FluidFM solutions Cytosurge brings significant benefits to a wide range of applications in life sciences. More than 100 labs are already using FluidFM systems and go beyond conventional technological boundaries in CRISPR genome editing, mechanobiology, virology, single cell omics, neuroscience, and nanoprinting. We are driven by our common goal to enhance societal health and well-being by accelerating science through our unique solutions.
